Insider buying last 90 days
No open-market insider purchases were filed for MDLN in the last 90 days.
From Form 4 filings, dated to when each was filed.
Every MDLN insider filing, plotted on the chart in Gekko.Open MDLN in Gekko
NASDAQ: MDLN
Medline (MDLN) Stock Analysis & Forecast
Nov 4 close
$40.35+6.26 (+18.4%)
Gekko Brief
AI summaryNov 4 closeMedline's week centers on third-quarter results reported on 4 November, with revenue growth of 10% year over year to $7.9 billion, supported by gains across its Medline Brand and Supply Chain Solutions businesses. Separately, securities law firms including Bleichmar Fonti & Auld and Pomerantz have announced investigations into Medline tied to product quality issues and the stock's recent drops. Also this week, Medline confirmed that CEO Jim Boyle will present at the Jefferies Global Healthcare Conference in London on 17 November.
Shares closed at $40.35, up 18.4%, sitting between the 50-day average of $34.58 and the 200-day average of $39.53. The GekkoIndex reads 42.4, placing the stock in the Distribution zone, down 25.6 over the past five sessions. Gekko Fair Value stands at $51.62, putting the current price 21.8% below that level.
Looking ahead, no confirmed next earnings date appears on the calendar, with the last report filed 5 August showing EPS of $0.47 against an estimate of $0.30, followed by a 17.9% reaction. Average absolute reaction across the last four quarters runs 9.2%, with 4 of those quarters beating estimates. Analyst coverage shows 16 buy ratings against 2 holds among 18 firms, with a consensus target of $44.31, implying 9.8% upside. Typical 20-day movement for the stock runs 8.4%, worth keeping in mind amid the ongoing legal investigations.
Written by AI from the Nov 4, 2026 close and checked automatically against the figures on this page.
Medline price vs fair value
Close $40.35200-day averageGekko Fair Value $51.62
Medline quick facts
- Market cap
- $35.40B
- P/E ratio
- 80.1
- Forward P/E
- 19.6
- EPS, TTM
- $0.42
- Revenue, TTM
- $29.94B
- Profit margin
- 2.3%
- Dividend yield
- —
- Beta
- —
- Volume
- 25.42M avg 9.74M
- 1-year return
- —
- Typical daily move
- ±4%
- Typical 20-day move
- ±8.4%
- 50-day average
- $34.58
- 200-day average
- $39.53
- Next earnings
- —
- Shares outstanding
- 877.4M
Medline swing-trade checklist
Medline scores 1 supportive, 1 mixed and 1 headwind across the 3 checklist items with data.
Six things swing traders check before a 20-day hold, read from the latest data.
1 supportive1 mixed1 headwind
- Trendmixed
Averages disagree
Close $40.35 sits between the 50-day ($34.58) and 200-day ($39.53) averages, or the averages disagree.
See the chart - GekkoIndexheadwind
42.4, Distribution
Reading 42.4 is in the Distribution zone.
See the GekkoIndex - Fair valuesupportive
21.8% below
Price is 21.8% below Gekko Fair Value (more than 5% below).
See fair value - Smart moneyno data
No data
No insider, Congress or unusual options activity in the window.
See smart money - Earnings riskno data
No data
No confirmed report date on the calendar.
See earnings - Seasonalityno data
No data
Not enough years of history for a seasonal read.
A description of current data, not a recommendation. How this page works
Medline stock chart and price history
Medline closed at $40.35 on Nov 4, 2026, inside a 52-week range of $31.37 to $50.88.
Close50-day average200-day averageVolume
Use the left and right arrow keys to read daily values.
Performance Breakdown
- 1 month
- +13.5%
- 3 months
- +16.9%
- 6 months
- −4.0%
The full MDLN chart adds GekkoIndex, insider, options, Congress and hedge fund markers, plus TrendCandles™.Open MDLN in Gekko
Follow Medline through every session
Put MDLN on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.
Track MDLN in GekkoFree for 7 days. No credit card required.
About Medline
Medline makes medical and surgical products for healthcare organizations around the world, including hospitals, surgical centers, physician offices, and nursing and post-acute care facilities. It is known for supplying the everyday and specialized items these providers rely on, from patient care basics to equipment used in operating rooms and diagnostic labs.
The business runs through two main divisions. One produces and sources Medline's own branded goods, spanning frontline patient care items such as wound care and gloves, surgical supplies like drapes, gowns, PPE, instruments and implants, and laboratory and diagnostic tools including testing devices and monitoring systems. The other division sources and distributes third-party products, including recognized national brands, and provides logistics services such as warehousing, packaging, inventory management and route planning to customers both in the domestic market and abroad.
Medline was founded in 1966 and is headquartered in Northfield, Illinois. Its shares are listed on the NASDAQ under the ticker MDLN.
- Listed
- NASDAQ
- Sector
- Health technology
- Industry
- Medical specialties
- Website
- medline.com
Medline GekkoIndex: the smart money zone
Medline’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 42.4, in the Distribution zone, down 25.6 points over five sessions.
42.4Distribution
Down 25.6 points over five sessions, from the Accumulation zone.
Reading for Nov 4, 2026
What followed past readings in each zone
| Zone | Readings | 5 days | 20 days | ||
|---|---|---|---|---|---|
| Buying | 15 | −1.1% | +1.0% | ||
| Accumulation | 77 | +1.3% | +4.1% | ||
| Neutral | 117 | −1.3% | −5.4% | ||
| Distribution (current zone) | 5 | Too few readings yet | |||
| Selling | 0 | Not available | |||
Average MDLN share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Distribution readings averaged +1.2% over 20 days. Past behaviour doesn’t guarantee future results.
Distribution zone: Institutions potentially offloading. About the five zones →
See every daily GekkoIndex reading plotted over the MDLN price, zone by zone.Track MDLN in Gekko
Is Medline stock overvalued? Gekko Fair Value
Medline trades 21.8% below Gekko Fair Value of $51.62, so the shares are undervalued on Gekko’s estimate.
Gekko’s own estimate of what Medline shares are worth, recalculated every trading day.
$51.62
Gekko Fair Value, Nov 4, 2026
21.8% Undervalued
At the end of Aug 2026 the price was 34.6% below the estimate.
Gekko Fair ValueShare price, month end
Gekko Fair Value on every chart, with the gap to price updating daily.Open MDLN in Gekko
Medline insider and Congress trading
No open-market insider purchases were filed for Medline, and no Congress trades were disclosed, in the last 90 days.
Plus buybacks, unusual options and fund positions, each dated to when it became public.
Congress trades last 90 days
No trades in MDLN were disclosed by members of Congress in the last 90 days.
From congressional disclosures, which report amounts as ranges.
Congress disclosures for MDLN, plotted on the chart in Gekko.Open MDLN in Gekko
Buybacks
Medline has been buying back its own shares.
- Bought back, quarter ended Dec 31, 2025
- $1.97B
- As a share of market cap
- 5.56%
- Trailing four quarters
- $2.01B
From company filings.
Hedge funds and billionaires quarter ended Jun 30
4of the funds Gekko tracks hold MDLN.
2added1opened1trimmed0sold out
Which funds are on each side, name by name.Unlock in Gekko
Medline earnings: next date and track record
Medline beat the EPS estimate in 4 of its last 4 reports, moving 9.2% on average across the report.
4 of 4reports beat the EPS estimate
±9.2%average move across the report
0 of 3reports followed by a gain
Share-price move across each report
Last earnings call, Aug 5, 2026 AI summary
- What they said
- Medline reported strong second-quarter performance with 12% year-over-year net sales growth to $7.7 billion and first-half sales up 11% to $15 billion. Medline Brand sales grew 7% and Supply Chain Solutions grew 16%, driven by new customer signings and expansion with existing customers. Adjusted EBITDA increased 13% year-over-year to $1.1 billion, which included a net IEEPA tariff benefit of roughly $240–243 million; underlying adjusted EBITDA was $817 million. Management raised its fiscal year organic sales outlook but moderated its adjusted EBITDA outlook due to several headwinds: Middle East conflict impacts (estimated $70 million in 2026), the Tracy warehouse fire, growth-related operational investments, quality remediation, and softness in retail. Key operational initiatives include adding distribution centers (Texas, California, Midwest), adding automation (auto-stores), investments in quality and AI, and enterprise cost-savings initiatives. Prime vendor and customer signings totaled roughly $650–659 million year-to-date toward a $1 billion goal, and management expressed confidence in reaching $1 billion-plus. The company recorded and will remit customer repayments tied to IEEPA tariff refunds (total available $507 million, recorded net benefit ~ $240–243 million, customer accrual ~ $89 million), and assumes tariff rates at ~10% for the remainder of the year. Supply Chain Solutions adjusted EBITDA margin was ~4.9% in the quarter and is expected to land around 4.9%–5% for the year.
- Guidance
- Raised fiscal year organic sales outlook (no specific consolidated sales figure disclosed on the call). Adjusted EBITDA outlook moderated (management provided no new explicit annual adjusted EBITDA number on the call but emphasized the need to absorb several headwinds). Management estimated a $70 million 2026 impact from the Middle East (assumes diesel fuel roughly $5) and assumed tariff rates remain at the new ~10% level for the rest of the year. Supply Chain Solutions margin expected around 4.9%–5%. Management plans to make customer repayments tied to IEEPA refunds in the latter part of the year. Target of $1 billion+ in prime vendor signings remains intact; $650–659 million achieved year-to-date.
- Risks flagged
- Middle East conflict and associated fuel/raw material cost volatility; Tracy warehouse fire and related operational disruption; ongoing quality remediation efforts and product delays; tariff uncertainty and past IEEPA tariff impacts; retail softness and customer-specific losses; inflation and raw-material input cost volatility (e.g., NBR for gloves, resins); short-term margin pressure from growth-related operational investments and first-year rebate structures on new signings.
| Reported | EPS | Revenue | Move |
|---|---|---|---|
| Aug 5, 2026 | $0.47 est $0.30 | $7.69B est $7.52B | −17.9% |
| May 6, 2026 | $0.33 est $0.29 | $7.35B est $7.16B | −7.6% |
| Feb 25, 2026 | $0.38 est $0.24 | $7.79B est $7.51B | −2.2% |
| Nov 4, 2025 | $0.31 est $0.00 | $7.12B | — |
“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.
Medline stock forecast and analyst price targets
Analysts’ average 12-month price target for Medline is $44.31, +9.8% from the last close, from 18 firms rating the stock in the last 90 days.
$44.31consensus 12-month target, +9.8% from the last close
Now $40.35Avg $44.31
Low $34High $55
Each firm’s latest rating in the last 90 days: 18 firms.
Latest analyst actions
| Date | Firm | Target | vs price |
|---|---|---|---|
| Nov 4 | Barclays | $43 | +6.6% |
| Oct 22 | Mizuho Securities | $45 | +11.5% |
| Oct 9 | Barclays | $43 | +6.6% |
| Oct 7 | Leerink Partners | $43 | +6.6% |
| Oct 6 | RBC Capital | $46 | +14.0% |
±4%typical daily move, from the 14-day average range
Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.
Medline market cap and key statistics
Medline’s market cap is $35.40B, with a P/E ratio of 80.1 and revenue of $29.94B over the last twelve months.
Valuation
- Market cap
- $35.40B
- P/E ratio
- 80.1
- Forward P/E
- 19.6
- EPS, TTM
- $0.42
- Gekko Fair Value
- $51.62
Trading
- Volume
- 25.42M
- Avg volume, 20 days
- 9.74M
- 52-week high
- $50.88
- 52-week low
- $31.37
- Shares outstanding
- 877.4M
Financials
- Revenue, TTM
- $29.94B
- Profit margin
- 2.3%
- Return on equity
- 4.9%
- Quarterly earnings growth, YoY
- +262.0%
Risk and income
- Typical daily move
- ±4%
- Typical 20-day move
- ±8.4%
Medline stock news this week
6 headlines about Medline from the past week, newest first, each linking to the publisher.
- Medline Q3 Earnings Call HighlightsMarketBeat, Nov 4
- Medline (MDLN) Reports Q3 Earnings: What Key Metrics Have to SayZacks Investment Research, Nov 4
- Medline Reports Third Quarter and Nine Months 2026 ResultsGlobeNewsWire, Nov 4
- MDLN Investigation Reminder: Medline Product Quality Issues Trigger Securities Fraud Investigation for Investors – Contact BFA Law if You Lost MoneyGlobeNewsWire, Nov 4
- Medline announces participation in the 2026 Jefferies Global Healthcare ConferenceGlobeNewsWire, Nov 2
- GIC Reports 13.03% Ownership Stake in Medline Inc. Class A SharesKalkine Media, Oct 30
Medline peers
Medline’s 6 largest industry peers by market value, with today’s move, GekkoIndex zone and gap to Gekko Fair Value.
| Stock | GekkoIndex zone | vs Fair Value |
|---|---|---|
| TMOThermo Fisher Scientific | Neutral | 14.5% above |
| ABTAbbott Laboratories | Distribution | 8.0% below |
| ISRGIntuitive Surgical | Distribution | 30.4% above |
| DHRDanaher | Neutral | 3.6% above |
| MDTMedtronic | Neutral | 16.0% below |
| SYKStryker | Distribution | 6.5% above |
A peer links to its own page where one exists.
Medline stock FAQ
What is Medline’s market cap?
Medline’s market cap is $35.40B at the Nov 4, 2026 close of $40.35, with 877.4M shares outstanding. The shares trade on a P/E ratio of 80.1.
What is the Medline stock forecast?
The consensus analyst 12-month price target for Medline is $44.31, +9.8% from the last close. Of the 18 firms that rated the stock in the last 90 days, 16 rate it a buy, 2 a hold and 0 a sell. Gekko doesn’t publish price predictions of its own.
Is Medline stock overvalued or undervalued?
On Gekko’s estimate Medline is undervalued: the Nov 4, 2026 close of $40.35 is 21.8% below Gekko Fair Value of $51.62. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.
What is Medline’s 52-week high and low?
Medline’s 52-week high is $50.88 and its 52-week low is $31.37; it closed at $40.35 on Nov 4, 2026.
Is Medline stock a buy right now?
Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 1 of the 3 items with data read as supportive (fair value), 1 as mixed (trend) and 1 as a headwind (gekkoindex). The checklist is a description of current data, not a recommendation.
How this page works
During US trading hours the price at the top of the page is a delayed quote, refreshed every 15 minutes; everything else is rebuilt after each US market close. The GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →
See Medline the way Gekko members do
Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.
Join 1,461 other traders using Gekko
Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.